Table 2.
Univariate and multivariate Cox regression analysis for OS.
| Univariate Cox model | Multivariate Cox model | |||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Age | 1.034 (1.024-1.045) | < 0.001 | 1.024 (1.011 -1.037) | 0.001 |
| Female | 0.988 (0.705-1.384) | 0.944 | – | – |
| III–IV stage | 2.140 (1.429-3.204) | < 0.001 | 1.899 (1.194 -3.02) | 0.014 |
| ASCT | 0.505 (0.305-0.836) | 0.008 | 0.478 (0.242 -0.945) | 0.034 |
| PR to the 1st treatment | 2.824 (2.060-3.873) | < 0.001 | 2.687 (1.859 -3.884) | < 0.001 |
| ALK+ALCL | 0.101 (0.041-0.245) | < 0.001 | 0.478 (0.242 -0.945) | 0.003 |
| ECOG ≥2 (%) | 1.507 (0.851-2.668) | 0.159 | – | – |
| LDH ≥ULN (%) | 1.531 (1.070-2.191) | 0.020 | 1.138 (0.774 -1.673) | 0.584 |
| B symptoms (%) | 1.112 (0.299-4.128) | 0.875 | – | – |
ALK+ALCL, anaplastic large-cell lymphoma; anaplastic lymphoma kinase positive; ECOG, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; ULN, upper limit of normal; HR, hazard ratio; ASCT, autologous stem cell transplantation; PR, partial response.